Friday Bristol-Myers Squibb Company (BMY) $BMY opened at 49.50 hitting the high price of 49.85 and a day low of 49.28 with a total volume of 8,288,199. BMY had a previous close of 49.52 and has been seeing an average volume of 8,524,680.
Overall Average: 56% Sell
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
1 Pipeline All Investors Need to Know
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 4:05PM CDT
In this segment from Tuesday's Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass look at Merck , and why its pipeline is one investors should be excited about today. Amazingly, Merck looks as though it will... (full story)
Key Takeaways from Bristol-Myers Squibb's Earnings
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 02, 5:30PM CDT
Bristol-Myers Squibb reported mixed earnings for first quarter 2014 -- revenue declined by about 1% to $3.8 billion, as a decline in U.S. revenue of 10% was almost offset by a 10% lift in international revenue. Gross margin increased slightly to... (full story)
Final Glance: Pharmaceuticals companies
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Midday Glance: Pharmaceuticals companies
AP - Fri May 02, 12:30PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Early Glance: Pharmaceuticals companies
AP - Fri May 02, 9:33AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Approvals from the European Commission and Release of Quarterly Financial Results - Analyst Notes on Merck, Johnson & Johnson, Bristol-Myers Squibb, Teva and AbbVie
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1946-100free. (full story)
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained? (full story)
CRL for The Medicines Co.'s Cangrelor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:05PM CDT
The FDA issued a CRL to The Medicines Co.'s (MDCO) NDA for cangrelor. (full story)
Global Metastatic Colorectal Cancer Clinical Trials Review 2014: Espy the Commercial Landscape of the Major Institutes & Companies
M2 - Thu May 01, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jtbsc/metastatic) has announced the addition of the "Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Colorectal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Colorectal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Colorectal Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Pfizer Inc. - E. Merck KG - Eli Lilly and Company - Bristol-Myers Squibb Company - Novartis AG - Bayer AG - AstraZeneca PLC - National Cancer Institute - Memorial Sloan Kettering Cancer Center - The University of Texas M. D. Anderson Cancer Center - Grupo Espanol de Tratamiento de Tumores Digestivos - Epidemiological and Clinical Research Information Network - European Organization for Research and Treatment of Cancer - Gruppo Oncologico del Nord-Ovest - NCIC Clinical Trials Group - Duke University For more information visit http://www.researchandmarkets.com/research/4jtbsc/metastatic (full story)
Technical Recap on Pharma Equities -- Research on Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu May 01, 8:16AM CDT
On Wednesday, April 30, 2014, the NASDAQ Composite ended at 4,114.56, up 0.27%, the Dow Jones Industrial Average advanced 0.27%, to finish the day at 16,580.84, and the S&P 500 closed at 1,883.95, up 0.30%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 672.95, up 0.14%, with the index advancing 3.87% in the previous three months. Investor-Edge has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly & Company (NYSE: LLY) and GlaxoSmithKline PLC (NYSE: GSK). Free technical research on BMY, AZN, LLY and GSK can be downloaded upon signing up at: (full story)
Global Metastatic Prostate Cancer Clinical Trials Review 2014: Espy the 20 Leading Companies/Institutions
M2 - Thu May 01, 7:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/thv65g/metastatic) has announced the addition of the "Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Prostate Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Johnson & Johnson - Astellas Pharma Inc. - AstraZeneca PLC - Medivation, Inc. - Sanofi - Ipsen S.A. - Bristol-Myers Squibb Company - Pfizer Inc. - Novartis AG - Eli Lilly and Company - National Cancer Institute - European Organization for Research and Treatment of Cancer - Memorial Sloan Kettering Cancer Center - Barbara Ann Karmanos Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Southwest Oncology Group - OHSU Knight Cancer Institute - Swiss Group for Clinical Cancer Research - National Prostate Cancer Treatment Group - UNICANCER Group For more information visit http://www.researchandmarkets.com/research/thv65g/metastatic (full story)
Research and Markets: Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
Business Wire - Thu May 01, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9fbq3/organ) has announced the addition of the "Worldwide Organ Preservation Solutions Market 2013 - 2019" report to their offering. (full story)
Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
M2 - Thu May 01, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5ms2f/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K?hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc. This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved, type of preservation techniques used and the major geographic markets. The global market for organ preservation solutions has been segmented into nine major solutions that include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). On the basis of preservation techniques, the market has been segmented into three categories namely hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for each solution type, technique type and geographic region. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments. The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. This section also covers a market attractiveness analysis (by geography) for the year 2012 and Porter's five forces analysis for the global organ preservation solutions market. Market share (%) for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. The report also includes company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Aging global population - Global rate of aging population - Technological advancements - Increasing reimbursement scenario - Increase in per capita healthcare expenditure - Lack of organ donors - Widening Gap Between Patients Receiving Organ Transplants and Number of Donors in the U.S. (1998 - 2010) - High cost of procedure - Collaboration with research-oriented organizations and medical institutes to ensure retention of customer base - Porter's Five Force Analysis for the Global Organ Preservation Solutions Market Chapter 4 Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Viaspan - Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution - Renograf - Hypothermosol - Perfadex - Lifor - Human bioSystem (HBS) Solution - siRNA Transplant Solution - Others Chapter 5 Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Hypothermic Perfusion Preservation (HPP) - Static Cold Storage (SCS) Chapter 6 Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations - Long term contracts with healthcare service providers - Broadening of distribution network - Product innovation Chapter 9 Company Profiles - 21st Century Medicine - BioLife Solutions, Inc. - BioTime, Inc. - Bristol-Myers Squibb - Claris Lifesciences Limited - CryoLife, Inc. - Dr. Franz K?hler Chemie GmbH - Lifeline Scientific - Teva Pharmaceutical Industries Ltd. - ToleroTech, Inc. - XVIVO Perfusion AB For more information visit http://www.researchandmarkets.com/research/z5ms2f/organ (full story)
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be... (full story)
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent... (full story)
Overall Average: 56% Sell
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
1 Pipeline All Investors Need to Know
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 03, 4:05PM CDT
In this segment from Tuesday's Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass look at Merck , and why its pipeline is one investors should be excited about today. Amazingly, Merck looks as though it will... (full story)
Key Takeaways from Bristol-Myers Squibb's Earnings
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 02, 5:30PM CDT
Bristol-Myers Squibb reported mixed earnings for first quarter 2014 -- revenue declined by about 1% to $3.8 billion, as a decline in U.S. revenue of 10% was almost offset by a 10% lift in international revenue. Gross margin increased slightly to... (full story)
Final Glance: Pharmaceuticals companies
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Midday Glance: Pharmaceuticals companies
AP - Fri May 02, 12:30PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Early Glance: Pharmaceuticals companies
AP - Fri May 02, 9:33AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Approvals from the European Commission and Release of Quarterly Financial Results - Analyst Notes on Merck, Johnson & Johnson, Bristol-Myers Squibb, Teva and AbbVie
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1946-100free. (full story)
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained? (full story)
CRL for The Medicines Co.'s Cangrelor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:05PM CDT
The FDA issued a CRL to The Medicines Co.'s (MDCO) NDA for cangrelor. (full story)
Global Metastatic Colorectal Cancer Clinical Trials Review 2014: Espy the Commercial Landscape of the Major Institutes & Companies
M2 - Thu May 01, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jtbsc/metastatic) has announced the addition of the "Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Colorectal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Colorectal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Colorectal Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Pfizer Inc. - E. Merck KG - Eli Lilly and Company - Bristol-Myers Squibb Company - Novartis AG - Bayer AG - AstraZeneca PLC - National Cancer Institute - Memorial Sloan Kettering Cancer Center - The University of Texas M. D. Anderson Cancer Center - Grupo Espanol de Tratamiento de Tumores Digestivos - Epidemiological and Clinical Research Information Network - European Organization for Research and Treatment of Cancer - Gruppo Oncologico del Nord-Ovest - NCIC Clinical Trials Group - Duke University For more information visit http://www.researchandmarkets.com/research/4jtbsc/metastatic (full story)
Technical Recap on Pharma Equities -- Research on Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu May 01, 8:16AM CDT
On Wednesday, April 30, 2014, the NASDAQ Composite ended at 4,114.56, up 0.27%, the Dow Jones Industrial Average advanced 0.27%, to finish the day at 16,580.84, and the S&P 500 closed at 1,883.95, up 0.30%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 672.95, up 0.14%, with the index advancing 3.87% in the previous three months. Investor-Edge has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly & Company (NYSE: LLY) and GlaxoSmithKline PLC (NYSE: GSK). Free technical research on BMY, AZN, LLY and GSK can be downloaded upon signing up at: (full story)
Global Metastatic Prostate Cancer Clinical Trials Review 2014: Espy the 20 Leading Companies/Institutions
M2 - Thu May 01, 7:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/thv65g/metastatic) has announced the addition of the "Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Prostate Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Johnson & Johnson - Astellas Pharma Inc. - AstraZeneca PLC - Medivation, Inc. - Sanofi - Ipsen S.A. - Bristol-Myers Squibb Company - Pfizer Inc. - Novartis AG - Eli Lilly and Company - National Cancer Institute - European Organization for Research and Treatment of Cancer - Memorial Sloan Kettering Cancer Center - Barbara Ann Karmanos Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Southwest Oncology Group - OHSU Knight Cancer Institute - Swiss Group for Clinical Cancer Research - National Prostate Cancer Treatment Group - UNICANCER Group For more information visit http://www.researchandmarkets.com/research/thv65g/metastatic (full story)
Research and Markets: Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
Business Wire - Thu May 01, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9fbq3/organ) has announced the addition of the "Worldwide Organ Preservation Solutions Market 2013 - 2019" report to their offering. (full story)
Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
M2 - Thu May 01, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5ms2f/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K?hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc. This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved, type of preservation techniques used and the major geographic markets. The global market for organ preservation solutions has been segmented into nine major solutions that include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). On the basis of preservation techniques, the market has been segmented into three categories namely hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for each solution type, technique type and geographic region. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments. The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. This section also covers a market attractiveness analysis (by geography) for the year 2012 and Porter's five forces analysis for the global organ preservation solutions market. Market share (%) for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. The report also includes company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Aging global population - Global rate of aging population - Technological advancements - Increasing reimbursement scenario - Increase in per capita healthcare expenditure - Lack of organ donors - Widening Gap Between Patients Receiving Organ Transplants and Number of Donors in the U.S. (1998 - 2010) - High cost of procedure - Collaboration with research-oriented organizations and medical institutes to ensure retention of customer base - Porter's Five Force Analysis for the Global Organ Preservation Solutions Market Chapter 4 Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Viaspan - Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution - Renograf - Hypothermosol - Perfadex - Lifor - Human bioSystem (HBS) Solution - siRNA Transplant Solution - Others Chapter 5 Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Hypothermic Perfusion Preservation (HPP) - Static Cold Storage (SCS) Chapter 6 Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations - Long term contracts with healthcare service providers - Broadening of distribution network - Product innovation Chapter 9 Company Profiles - 21st Century Medicine - BioLife Solutions, Inc. - BioTime, Inc. - Bristol-Myers Squibb - Claris Lifesciences Limited - CryoLife, Inc. - Dr. Franz K?hler Chemie GmbH - Lifeline Scientific - Teva Pharmaceutical Industries Ltd. - ToleroTech, Inc. - XVIVO Perfusion AB For more information visit http://www.researchandmarkets.com/research/z5ms2f/organ (full story)
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be... (full story)
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent... (full story)
